Topic archive

psyence biomedical ltd.

11 stories

10/5/2026

AdvisorShares Trust holds 6.78% stake in Psyence Biomedical

The investment firm reports significant ownership in Psyence Biomedical as of September 2026.

10/5/2026

Agreement aims to produce pharmaceutical-grade ibogaine in Texas facility.

9/28/2026

Texas subsidiary gains exclusive U.S. rights to PsyLabs' ibogaine

9/28/2026

Texas subsidiary gains rights to ibogaine hydrochloride for drug development.

9/23/2026

Psyence BioMed to invest $5M in PsyLabs, plans Texas ibogaine trial.

9/23/2026

Company invests $5 million in PsyLabs for ibogaine research and production.

9/23/2026

Psyence and PsyLabs collaborate to advance ibogaine for opioid use disorder.

9/14/2026

Texas Ibogaine Research Corporation to spearhead U.S. ibogaine development efforts.

9/2/2026

The filing could signal strategic developments for the company.

8/19/2026

U.S. federal actions could accelerate ibogaine's medical potential

8/7/2026

Psyence Biomedical outlines its focus on psychedelic therapeutics for mental health in a recent investor update.